A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Latest Information Update: 23 May 2025
At a glance
- Drugs Sevasemten (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms FOX
- Sponsors Edgewise Therapeutics
Most Recent Events
- 08 May 2025 Status changed from recruiting to active, no longer recruiting.
- 08 May 2025 According to an Edgewise Therapeutics media release, the company is on track to report data from this study in 2Q 2025.
- 13 Jan 2025 According to an Edgewise Therapeutics media release, data from the study expected in in the first half of 2025.